MENU

COVID-19 RNA and DNA vaccines

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Professor, Department of Microbiology, University of Washington School of Medicine, Division Chief, Infectious Diseases and Translational Medicine, Washington National Primate Research Center
    Biography

      Dr. Deborah Fuller is a Professor in the Department of Microbiology at the University of Washington School of Medicine and Chief of the Infectious Diseases and Translational Medicine Division at the Washington National Primate Research Center. Prior to her academic career, Dr. Fuller worked in biotechnology developing vaccines against HIV, HBV and emerging infectious diseases. In 2004, she transitioned to academia where she is leading a team developing nucleic acid vaccine platform technologies and investigating immune mechanisms of protection and pathogenesis of viral infections. She recently developed a vaccine for COVID-19 that is scheduled to enter human clinical trials in Fall 2020. Dr. Fuller is a co-founder of a biotechnology company, Orlance, Inc (www.orlance.com) that aims to advance nucleic acid vaccines to clinical testing. She is currently a member of the National Institute of Allergy and Infectious Diseases (NIAID) Vaccines for Microbial Diseases (VMD) study section and serving on the leadership team for the Nonhuman Primate COVID Vaccines and Therapeutics Evaluation Network to accelerate the development of promising COVID-19 vaccines and antivirals. She has led translation of two vaccines from bench to clinical trials, authored 80 manuscripts and is a co-inventor on over a dozen patents for vaccines and antivirals.


    Abstract

    Learning Objectives:

    1. Learn what RNA and DNA vaccines are and why they are ideal vaccine strategies to respond rapidly to pandemics

    2. Understand the key requirements of an effective vaccine for COVID19

    3. Learn what made accelerated development of COVID19 vaccines possible


    Show Resources
    You May Also Like
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    SEP 17, 2020 2:00 PM PDT
    C.E. CREDITS
    SEP 17, 2020 2:00 PM PDT
    Learning Objectives: 1. Understanding the integral value of collaboration for advancement in scientific research; how to establish and grow academic, Pharma, and industry connections 2. Lear...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    Loading Comments...
    Show Resources
    Event Countdown
    • 0 Days
    • 0 Hours
    • 0 Minutes
    • 0 Seconds
    Attendees
    • See more